CliffBio
small molecule

ENSTILAR

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

Loss of exclusivityDecember 2031latest FDA-listed patent expiry
CompanyLEO PHARMA AS

Drug detail

Brand nameENSTILAR
Active ingredientBETAMETHASONE DIPROPIONATE; CALCIPOTRIENE
Strength0.064%;0.005%
Dosage formAEROSOL, FOAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalOctober 2015
Marketing statusRX

Listed patents

PatentExpiresType
9119781*PEDDecember 2031—
10130640*PEDDecember 2031—
10660908June 2031product
9566286June 2031product
10130640June 2031product
9119781June 2031product
10682364June 2031product
10716799June 2031product
10617698June 2031product
10688108June 2031use U-2627

More from LEO PHARMA AS

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ENSTILAR patent cliff — loss of exclusivity December 2031 | CliffBio